Exacerbation of antigen-induced arthritis in urokinase-deficient mice

Journal of Clinical Investigation

Volumn 102, Issue 1, 1998, Pages 41-50

  Busso, Nathalie ^a   Péclat, Véronique ^a   Van Ness, Karen ^a   Kolodziesczyk, Eric ^b   Degen, Jay ^c   Bugge, Thomas ^c   So, Alexander ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Arthritis; Fibrin; Inflammation; Plasmin; Urokinase

Indexed keywords

FIBRIN; PLASMIN; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTHRITIS; ARTICLE; BONE MATRIX; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; EXTRACELLULAR MATRIX; INFLAMMATION; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS;

EID: 2642616219     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2312     Document Type: Article

References (55)

1. Firestein, G.S. 1997. Etiology and pathogenesis of rheumatoid arthritis. In Textbook of Rheumatology. W.N. Kelley, E.D. Harris, S. Ruddy, and C.B. Sledge, editors. W.B. Saunders Co., Philadelphia. 851-897.
2. Dano, K., P.A. Andreasen, J. Grondahl-Hansen, P. Kristensen, L.S. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:139-266.
3. Vassalli, J.D., A.P. Sappino, and D. Belin. 1991. The plasminogen activator/plasmin system. J. Clin. Invest. 88:1067-1072.
4. r 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100:86-92.
5. Ossowski, L., G. Clunie, M.T. Masucci, and F. Blasi. 1991. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 115:1107-1112.
6. Hamilton, J.A., I.K. Campbell, J. Wojta, and D. Cheung. 1991. Plasminogen activators and their inhibitors in arthritic disease. Ann. NY Acad. Sci. 667: 87-100.
7. Busso, N., V. Péclat, A. So, and A.-P. Sappino. 1997. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann. Rheum. Dis. 56:550-557.
8. Weinberg, J.B., A.M. Pippen, and C.S. Greenberg. 1991. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 34:996-1005.
9. Ronday, H.K., H.H. Smits, G.N. van Muijen, M.S. Pruszcynski, R.J. Dolhain, E.J. van Langelaan, F.C. Breedveld, and J.H. Verheijen. 1996. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br. J. Rheumatol. 35:416-423.
10. Brommer, E.J., G. Dooijewaard, B.A. Dijkmans, and F.C. Breedveld. 1992. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb. Haemost. 68:180-184.
11. Saxne, T., I. Lecander, and P. Geborek. 1993. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J. Rheumatol. 20:91-96.
12. Belcher, C. F. Fawthrop, R. Bunning, and M. Doherty. 1996. Plasminogen activators and their inhibitors in synovial fluid from normal, osteoarthritis, and rheumatoid arthritis knees. Ann. Rheum. Dis. 55:230-236.
13. Werb, Z., and C.M. Alexander. 1993. Proteinases and Matrix Degradation. In Textbook of Rheumatology. W.N. Kelley, E.D. Harris, S. Ruddy, and C.B. Sledge, editors. W.B. Saunders Co., Philadelphia. 248-268.
14. Werb, Z., C.L. Mainardi, C.A. Vater, and E.D. Harris, Jr. 1977. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N. Engl. J. Med. 296:1017-1023.
15. Murphy, G., S. Atkinson, R. Ward, J. Gavrilovic, and J.J. Reynolds. 1992. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. NY Acad. Sci. 667:1-12.
16. Campbell, I.K., D.S. Piccoli, M.J. Roberts, K.D. Muirden, and J.A. Hamilton. 1990. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum. 33:542-552.
17. Ronday, H.K., H.H. Smits, P.H.A. Quax, G. Van Der Pluijm, C.W.G.M. Làwik, F.C. Breedveld, and J.H. Verheijen. 1996. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br. J. Rheumatol. 36:9-15.
18. Jasani, M.K. 1978. Fibrin: metabolism, immunopathogenesis and significance in rheumatoid arthritis. In Immunopathogenesis of Rheumatoid Arthritis. G.S. Panayi and P.M. Johnson, editors. Red Books, Surrey. 137-146.
19. Zacharski, L.R., F.E. Brown, V.A. Memoli, W. Kisiel, B.J. Kudryk, S.M. Rousseau, J.A. Hunt, C. Dunwiddie, and E.M. Nutt. 1992. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin. Immunol. Immunopathol. 63:155-162.
20. Collen, D., and H.R. Lijnen. 1992. Fibrin-specific fibrinolysis. Ann. NY Acad. Sci. 667:259-271.
21. Rabbani, S.A., A.P. Mazar, S.M. Bernier, M. Haq, I. Bolivar, J. Henkin, and D. Goltzman. 1992. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase activity. FEBS Lett. 267:14151-14156.
22. Busso, N., S.K. Masur, D. Lazega, S. Waxman, and L. Ossowski. 1994. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126: 259-270.
23. Waltz, D.A., and H.A. Chapman. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269:14746-14750.
24. Carmeliet, P., L. Schoonjans, L. Kieckens, B. Ream, J. Degen, R. Bronson, R. De Vos, J.J. van den Oord, D. Collen, and R.C. Mulligan. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:419-424.
25. Bugge, T.H., M.J. Flick, C.C. Daugherty, and J.L. Degen. 1995. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9:794-807.
26. Bugge, T.H., K.W. Kombrinck, O. Xiao, K. Holmbäck, C.C. Daugherty, D.P. Witte, and J.L. Degen. 1997. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood. 90:4522-4531.
27. Brackertz, D., G.F. Mitchell, and I.R. Mackay. 1977. Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum. 20:841-850.
28. Sappino, A.P., J. Huarte, J.D. Vassalli, and D. Belin. 1991. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J. Clin. Invest. 87:962-970.
29. Meacock, S.C., D.R. Brandon, C.P. Brown, and B.P. Swann. 1992. A novel technique for immunohistoperoxidase staining of unfixed whole joints of small animals. Histochem. J. 24:115-119.
30. Vassalli, J.D., and D. Belin. 1987. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 214:187-191.
31. Kleiner, D.E., and W.G. Stetler-Stevenson. 1994. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218:325-329.
32. 99mTc-pertechnetate uptake. Agents Actions. 11: 640-642.
33. Bell, W.R., S.S. Shapiro, J. Martinez, and H.L. Nossel. 1978. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. Rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. J. Lab. Clin. Med. 91:592-604.
34. Takeda, Y. 1969. Studies of the metabolism and distribution of fibrinogen in patients with rheumatoid arthritis. J. Lab. Clin. Med. 69:624-633.
35. Yamamoto, K., and D.J. Loskutoff. 1996. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J. Clin. Invest. 97: 2440-2451.
36. Eitzman, D.T., R.D. McCoy, X. Zheng, W.P. Fay, T. Shen, D. Ginsburg, and R.H. Simon. 1996. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97:232-237.
37. Barazzone, C., D. Belin, P.-F. Piguet, J.-D. Vassalli, and A.-P. Sappino. 1996. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J. Clin. Invest. 98:2666-2673.
38. Romer, J., T.H. Bugge, C. Pyke, L.R. Lund, M.J. Flick, J.L. Degen, and K. Dano. 1996. Impaired wound healing in mice with a disrupted plasminogen gene. Nat. Med. 2:287-292.
39. Kitching, A.R., S.R. Holdsworth, V.A. Ploplis, E.F. Plow, D. Collen, P. Carmeliet, and P.G. Tipping. 1997. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J. Exp. Med. 185: 963-968.
40. Carmassi, F., F. De Negri, M. Morale, R. Puccetti, and S.I. Chung. 1994. Elastase-and plasmin-mediated fibrinolysis in rheumatoid arthritis. Int. J. Tissue React. 16:89-93.
41. Bos, R., C.J. van Leuven, J. Stolk, P.S. Hiemstra, H.K. Ronday, and W. Nieuwenhuizen. 1997. An enzyme immunoassay for polymorphonuclear leucocyte-mediated fibrinogenolysis. Eur. J. Clin. Invest. 27:148-156.
42. Suh, T.T., K. Holmback, N.J. Jensen, C.C. Daugherty, K. Small, D.I. Simon, S. Potter, and J.L. Degen. 1995. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9: 2020-2033.
43. Perez, R.L., and J. Roman. 1995. Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J. Immunol. 154:1879-1887.
44. Dumonde, D.C., and L.E. Glynn. 1962. The production of arthritis in rabbits by an immunological reaction to fibrin. Br. J. Exp. Pathol. 43:373-383.
45. Bugge, T.H., K.W. Kombrinck, M.J. Flick, C.C. Daugherty, M.J.S. Danton, and J.L. Degen. 1996. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 87:709-719.
46. Tsirka, S.E., T.H. Bugge, J.L. Degen, and S. Strickland. 1997. Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin. Prof. Natl. Acad. Sci. USA. 94:9779-9781.
47. Gyetko, M.R., G.-H. Chen, R.A. McDonald, R. Goodman, G.B. Huffnagle, C.C. Wilkinson, J.A. Fuller, and G.B. Toews. 1996 Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J. Clin. Invest. 97:1818-1826.
48. Xiao, Q., M.J.S. Danton, D.P. Witte, M.C. Kowala, M.T. Valentine, T.H. Bugge, and J.L. Degen. 1997. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc. Natl. Acad. Sci. USA. 94:10335-10340.
49. Carmeliet, P., L. Moons, R. Lijnen, M. Baes, V. Lemaitre, P. Tipping, A. Drew, Y. Eeckhout, S. Shapiro, F. Lupu, and D. Collen. 1997. Urokinase-generated plasmin activates matrix metalloproteases during aneurism formation. Nat. Genet. 17:439-444.
50. van den Berg, W.B., F.A.J. van den Loo, P.L.E.M. van Lent, and L.A.B. Joosten. 1993. Mechanisms of cartilage destruction in joint inflammation. Agents Actions. 39:49-60.
51. Martel-Pelletier, J., R. McCollum, N. Fujimoto, K. Obata, J.M. Cloutier, and J.P. Pelletier. 1994. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab. Invest. 70:807-815.
52. Konig, A., R.C. Muhlbauer, and H. Fleisch. 1988. Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary (3H) tetracycline excretion from prelabeled mice. J. Bone Miner. Res. 3: 621-627.
53. Naldini, L., L. Tamagnone, E. Vigna, M. Sachs, G. Hartmann, W. Birchmeier, Y. Daikuhra, Y. Tsubouchi, F. Blasi, and P.M. Comoglio. 1992. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO (Eur. Mol. Biol. Organ.) J. 11:4825-4833.
54. Taketazu, F., M. Kato, A. Gobl, H. Ichijo, P. ten Dijke, J. Itoh, M. Kyogoku, J. Ronnelid, K. Miyazono, C.H. Heldin, et al. 1994. Enhanced expression of transforming growth factor-beta s and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab. Invest. 70:620-630.
55. Koch, A.E., M.M. Halloran, S. Hosaka, M.R. Shah, C.J. Haskell, S.K. Baker, R.J. Panos, G.K. Haines, G.L. Bennett, R.M. Pope, and N. Ferrara. 1996. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum. 39:1566-1575.